Hold the Presses is your online newsportal en brings press releases from around the world. Journalists can use it for free, although it is their responsibilty to check the news. Hold the Presses is in no way responsible for the content of the press releases, the Sender is. We hope you enjoy reading the news we bring you on this website. If a message is published that is not acceptable, we apologize. Please contact us and we will remove the message as soon as possible.

Thursday, 17 August 2017

ContextVision AB Q2 Financial Report

ContextVision AB    

Published: 08:00 CEST 17-08-2017 /GlobeNewswire /Source: ContextVision AB / : COV /ISIN: SE0000371239

ContextVision AB Q2 Financial Report

ContextVision Sees Highest Q2 Sales
STOCKHOLM - Aug. 17, 2017 -  ContextVision reached record-breaking sales in the second quarter 2017. Total sales reached 22,7 MSEK, 24 percent higher than second quarter last year. The progress within digital pathology is on track and a collaboration was initiated with a world-class research team in Uppsala.
ContextVision, a world-leading provider of medical image processing software, saw sales rising in every region. The company experienced particularly strong end-user demand in Asia, where sales increased by 32 percent.
"Chinese manufacturers have increased their focus on new technology to deliver higher quality products. As they strive for this higher quality, our products become even more necessary and attractive," said ContextVision's CEO, Anita Tollstadius.
Sales in Europe increased by six percent and the company saw positive development in the U.S. market, with a 56 percent increase in license sales due to strong orders from existing customers.
Ultrasound continues to be ContextVision's key market; the company's unique products in the category grew by more than 15 percent in the 2-D segment and 27 percent within 3-D. In addition, there was a strong growth from the XR products, with an increase of 61 percent, while MRI climbed 24 percent compared to second quarter last year.
During the quarter, ContextVision initiated a collaboration with a world-class research team in Uppsala to continue its progress within digital pathology.
"We have entered the product development phase within prostate cancer and added to our team. The project is running at full speed, and our new collaboration will add cutting-edge expertise, allowing us to develop unique products," Tollstadius said.
ContextVision will continue to invest significantly in research and development to support the commercial product offering and develop new innovative products and product features - all necessary for a platform of future growth.
For further information, please contact ContextVision's CEO, Anita Tollstadius, at +46 70 337 30 26.


About ContextVision
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV. For more information, please visit www.contextvision.com.

ContextVision Q2 2017 report

This announcement is distributed by Nasdaq Corporate Solutions (One Liberty Plaza, 165 Broadway, New York, NY 10006. Tel: +1 212 401 8700. www.nasdaqomx.com) on behalf of NASDAQ OMX Corporate Solutions clients. Source: ContextVision AB, Kungsgatan 50, Stockholm SE-111 35, Sweden
If you would like to unsubscribe and stop receiving these e-mails click here.